Package Insert Warnings and Liver Function Tests for CDK4/6 Inhibitors for Breast Cancer

This cohort study examines the utilization and timing of liver function tests among patients with breast cancer treated with cyclin-dependent kinase 4/6 inhibitors as recommended by the Food and Drug Administration insert warnings for these drugs.

Corresponding Author: Daniel C. Beachler, PhD, Staff VP, Safety daniel.beachler@carelon.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.